3 August 2015 - The fixed-ratio combination of the two drugs insulin degludec and liraglutide (Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this fixed-ratio combination offers an added benefit over the appropriate comparator therapy.

Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer presented no studies suitable for the assessment. One of the reasons was that the design of two important studies led to an unfair comparison.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/insulin-degludec-plus-liraglutide-no-hint-of-added-benefit-in-type-2-diabetes.6801.html